William Waddill Sells 9,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) Director William Waddill sold 9,000 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $99.64, for a total transaction of $896,760.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $779,683. The trade was a 53.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Trading Down 4.7%

Shares of NASDAQ:PTGX traded down $4.64 on Monday, reaching $94.92. 816,649 shares of the company’s stock were exchanged, compared to its average volume of 735,036. The company has a fifty day moving average of $101.73 and a 200-day moving average of $92.11. Protagonist Therapeutics, Inc. has a twelve month low of $47.53 and a twelve month high of $107.84. The company has a market capitalization of $6.10 billion, a price-to-earnings ratio of -52.44 and a beta of 1.86.

Get Protagonist Therapeutics alerts:

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The firm had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. As a group, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 3.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PTGX shares. TD Cowen increased their price target on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. The Goldman Sachs Group reiterated a “neutral” rating and set a $110.00 price target on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Leerink Partners increased their price target on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Finally, Truist Financial increased their price target on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $115.21.

Check Out Our Latest Report on Protagonist Therapeutics

Hedge Funds Weigh In On Protagonist Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PTGX. Farther Finance Advisors LLC lifted its stake in Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the last quarter. Greenline Wealth Management LLC bought a new position in Protagonist Therapeutics in the 4th quarter valued at approximately $27,000. EverSource Wealth Advisors LLC raised its stake in shares of Protagonist Therapeutics by 138.9% during the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after acquiring an additional 314 shares during the last quarter. Abich Financial Wealth Management LLC bought a new position in shares of Protagonist Therapeutics during the third quarter valued at $62,000. Finally, Osaic Holdings Inc. raised its stake in shares of Protagonist Therapeutics by 79.5% during the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after acquiring an additional 525 shares during the last quarter. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.

Read More

• Five stocks we like better than Protagonist Therapeutics
• Why These Three Big Buybacks Are Sending Very Different Signals to Investors
• Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
• Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
• Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.